ストックスクリーナーアプリを入手
0.00
100.00%
-53.01
アフターアワーズ：
53.02
53.02
+
Soleno Therapeutics Inc (SLNO) 最新ニュース
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory - DirectorsTalk Interviews
SLNO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Soleno Therapeutics (SLNO) Holds Steady at $53.01: Consolidation Within Key BoundariesFactor Crowding - newsline.com
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact - TradingView
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating Zero Upside but Strong Cash Flow - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out - ACCESS Newswire
SLNO Technical Analysis & Stock Price Forecast - Intellectia AI
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire
[15-12G] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan
[EFFECT] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire
Soleno Therapeutics (SLNO) Investor Outlook: Navigating the Hold Ratings with Promising EPS and Cash Flow - DirectorsTalk Interviews
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo
Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000 Growth Index - marketscreener.com
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Merger cashes out Soleno (NASDAQ: SLNO) officer equity at $53 - Stock Titan
Soleno Therapeutics (SLNO) director’s shares and options cancelled for $53 cash in Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director equity canceled in $53-per-share merger - Stock Titan
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price - Stock Titan
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share - Stock Titan
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger - Stock Titan
Soleno (SLNO) SVP exits equity as merger pays $53 per share - Stock Titan
Soleno Therapeutics (SLNO) insider equity cashed out at $53 in Neocrine merger - Stock Titan
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes - Stock Titan
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com Nigeria
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock - Stock Titan
Soleno Therapeutics, Inc. Announces Resignation of Jennifer Fulk as Chief Financial Officer, Effective May 18, 2026 - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
1.04%
0.76%
大文字化:
|
ボリューム (24 時間):